Evidence map›Paper›PMID 24565992›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2014

Late cardiovascular complications after hematopoietic cell transplantation.

Eric J Chow, Kenneth Wong, Stephanie J Lee, Kara L Cushing-Haugen, Mary E D Flowers, Debra L Friedman, Wendy M Leisenring, Paul J Martin, Beth A Mueller, K Scott Baker

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 3 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Adipokines, Inflammation, and Adiposity in Hematopoietic Cell Transplantation Survivors.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Eric J ChowClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington. Electronic address: ericchow@u.washington.edu.
Kenneth WongDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Stephanie J LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
Kara L Cushing-HaugenPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Mary E D FlowersClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
Debra L FriedmanDepartment of Pediatrics, Vanderbilt University, Nashville, Tennessee.
Wendy M LeisenringClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Paul J MartinClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
Beth A MuellerPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
K Scott BakerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington.
Fred Hutch Cancer Center · USUniversity of California, Los Angeles · USVanderbilt University · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4M
Determinants of late cardiovascular morbidity among survivors of hematopoietic ceK07CA151775 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHOW, ERIC JESSEN · 2011 to 2015
$755k
Analysis of Morbidity and Mortality Among Hematopoietic Cell Transplantation SurvR03CA167451 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHOW, ERIC JESSEN · 2013 to 2014
$173k
NCI NIH HHS CA151775NCI NIH HHS CA15704NCI NIH HHS CA167451NCI NIH HHS CA18029NCI NIH HHS K07 CA151775NCI NIH HHS P01 CA018029NCI NIH HHS P30 CA015704NCI NIH HHS R03 CA167451
6 · The paper itself

Abstract

The authors sought to better understand the combined effects of pretransplant, transplant, and post-transplant factors in determining risks of serious cardiovascular disease after hematopoietic cell transplantation (HCT). Hospitalizations and deaths associated with serious cardiovascular outcomes were identified among 1379 Washington State residents who received HCT (57% allogeneic and 43% autologous) at a single center from 1985 to 2005, survived ≥ 2 years, and followed through 2008. Using a nested case-cohort design, relationships (hazard ratios [HRs]) between potential risk factors and outcomes were examined among affected survivors and a randomly selected subcohort (N = 509). After 7.0 years of median follow-up (range, 2.0 to 23.7), the 10-year cumulative incidence of ischemic heart disease, cardiomyopathy, stroke, and all-cause cardiovascular death was 3.8%, 6.0%, 3.5%, and 3.7%, respectively. In multivariable analysis, increased pretransplant anthracycline was associated with cardiomyopathy. Active chronic graft-versus-host disease was associated with cardiovascular death (HR, 4.0; 95% confidence interval, 1.1 to 14.7); risk was otherwise similar between autologous versus allogeneic HCT recipients. Independent of therapeutic exposures, pretransplant smoking, hypertension, dyslipidemia, diabetes, and obesity conferred additional risk of all outcomes except stroke (HR ≥ 1.5 for each additional risk factor, P < .03). Hypertension and dyslipidemia at 1 year with persistence of these conditions 2 or more years after HCT also were associated with independent risks of multiple outcomes. HCT survivors with preexisting or newly developed and persistent cardiovascular risk factors remain at greater risk of subsequent serious cardiovascular disease compared with other survivors, independent of chemo- and radiotherapy exposures. These survivors should receive appropriate follow-up and be considered for primary intervention.

Indexed as

AdultCardiovascular DiseasesCase-Control StudiesFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedSurvival AnalysisTransplantation ConditioningTreatment OutcomeYoung AdultCardiovascularHematopoietic cell transplantationLate effectsMortalitySurvivorship

Identifiers

PMID24565992
PMCPMC4019708
OpenAlexW2008285775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.